Avalo Therapeutics Inc

NASDAQ:AVTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Contact Information

Headquarters

540 Gaither Rd Ste 400ROCKVILLE, MD, United States 20850-6713

Phone

410-522-8707

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Garry Neil

Chief Financial Officer

Christopher Sullivan

Chief Medical Officer

Mittie Doyle

Lead Independent Director

Magnus Persson

Independent Director

June Almenoff